Back to Peptipedia
Sexual HealthApproved · US

PT-141

Bremelanotide

PT-141 is bremelanotide. VYLEESI has US approval for acquired, generalized HSDD in premenopausal women.

Approvals

US · Approved

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

PT-141 denotes bremelanotide, a defined melanocortin-receptor agonist peptide. The US approval applies to VYLEESI.

Human research
Strong
Replication
Single research group
Clinical endpoints
Symptom- or function-related
Safety
Characterized by prescribing information or extensive studies
Approval
US · Approved

The dimensions are presented separately and are not combined into an overall score.

What the source shows

Its indication is narrower than general libido enhancement.

Research gaps

  • ·Approval data cannot be generalized to other populations.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.